NEW YORK (GenomeWeb) – In a filing yesterday with the US Securities and Exchange Commission, BG Medicine said it has decided to voluntarily deregister its common stock and become a non-reporting company.

The company said it made this decision due to the "significant cost and resource demands of being a public company," noting as well that following deregistration it will no longer publish periodic financial information or furnish such information to its shareholders other than that which is required by law.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.